Let's Get Started

Biotech

5am Ventures Llc. is Buying Pulmatrix Inc. (NASDAQ:PULM) Shares

5am Ventures Llc. is Buying Pulmatrix Inc. (NASDAQ:PULM) Shares

Mar 29, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pulmatrix Inc. (NASDAQ:PULM) reported that 5am Ventures Llc. has picked up 251,188 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by 5am Ventures Llc. to a total of 251,188 representing less than 1.41% stake in the company.

For those not familiar with the company, Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

A glance at Pulmatrix Inc. (NASDAQ:PULM)’s key stats reveals a current market capitalization of 53.11 Million based on 17.83 Million shares outstanding and a price at last close of $3.23 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-06-15, Mcguire picked up 1,392 at a purchase price of $6.88. This brings their total holding to 52,722 as of the date of the filing.

On the sell side, the most recent transaction saw Oculus unload 922,500 shares at a sale price of $2.75. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pulmatrix Inc. (NASDAQ:PULM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) is Attracting Smart Money

Mar 29, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) reported that Longboard Capital Advisors, Llc. has picked up 1,312,000 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by Longboard Capital Advisors, Llc. to a total of 1,312,000 representing a 6.58% stake in the company.

For those not familiar with the company, Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

A glance at Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY)’s key stats reveals a current market capitalization of 85.48 Million based on 19.94 Million shares outstanding and a price at last close of $3.85 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-19, Lindstrom picked up 100,000 at a purchase price of $1.79. This brings their total holding to 100,000 as of the date of the filing.

On the sell side, the most recent transaction saw Miloni unload 110,000 shares at a sale price of $8.00. This brings their total holding to 468,576.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Rosalind Advisors, Inc. Picked Zosano Pharma Corp (NASDAQ:ZSAN) Shares

Rosalind Advisors, Inc. Picked Zosano Pharma Corp (NASDAQ:ZSAN) Shares

Mar 29, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Zosano Pharma Corp (NASDAQ:ZSAN) reported that Rosalind Advisors, Inc. has picked up 2,083,100 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by Rosalind Advisors, Inc. to a total of 2,083,100 representing a 5.5% stake in the company.

For those not familiar with the company, Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

A glance at Zosano Pharma Corp (NASDAQ:ZSAN)’s key stats reveals a current market capitalization of 62.47 Million based on 33.82 Million shares outstanding and a price at last close of $1.88 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-08-19, Erbez picked up 47,750 at a purchase price of $1.32. This brings their total holding to 47,750 as of the date of the filing.

On the sell side, the most recent transaction saw Barrett unload 1,099,996 shares at a sale price of $2.01. This brings their total holding to 952,809.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Zosano Pharma Corp (NASDAQ:ZSAN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Duggan Robert W is Buying Achaogen Inc. (NASDAQ:AKAO) Shares

Duggan Robert W is Buying Achaogen Inc. (NASDAQ:AKAO) Shares

Mar 28, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Achaogen Inc. (NASDAQ:AKAO) reported that Duggan Robert W has picked up 2,035,888 of common stock as of 2017-03-28.

The acquisition brings the aggregate amount owned by Duggan Robert W to a total of 2,035,888 representing a 5.7% stake in the company.

For those not familiar with the company, Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

A glance at Achaogen Inc. (NASDAQ:AKAO)’s key stats reveals a current market capitalization of 892.04 Million based on 35.78 Million shares outstanding and a price at last close of $23.90 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-19, Viswanathan picked up 500,000 at a purchase price of $13.50. This brings their total holding to 5,215,128 as of the date of the filing.

On the sell side, the most recent transaction saw Hillan unload 3,079 shares at a sale price of $26.58. This brings their total holding to 98,422.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Achaogen Inc. (NASDAQ:AKAO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Guess Who Picked Up Sunshine Heart Inc. (NASDAQ:SSH) Shares

Mar 28, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Sunshine Heart Inc. (NASDAQ:SSH) reported that Choi Ki Yong has picked up 245,000 of common stock as of 2017-03-28.

The acquisition brings the aggregate amount owned by Choi Ki Yong to a total of 245,000 representing a 9.1% stake in the company.

For those not familiar with the company, Sunshine Heart is a global medical device company founded by a cardiac surgeon that saw an incredible opportunity for how to treat heart failure. Heart failure (HF) affects millions and is a progressive condition that prevents patients from living normal lives. Sunshine Heart’s C-Pulse® Heart Assist System has CE Mark in Europe and is in a clinical study in the United States to determine if the C-Pulse System is safe and effective for treating moderate to severe heart failure. C-Pulse therapy is designed to reduce overall heart failure symptoms, improve quality of life, and reduce re-hospitalizations.

A glance at Sunshine Heart Inc. (NASDAQ:SSH)’s key stats reveals a current market capitalization of 4.68 Million based on 1.74 Million shares outstanding and a price at last close of $2.31 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-11-28, Erb picked up 80,000 at a purchase price of $0.22. This brings their total holding to 464,128 as of the date of the filing.

On the sell side, the most recent transaction saw Drayton unload 20 shares at a sale price of $5.27. This brings their total holding to 740.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Sunshine Heart Inc. (NASDAQ:SSH) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Just Picked Up Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) Shares

Here’s Who Just Picked Up Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) Shares

Mar 27, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) reported that Baker Bros. Advisors has picked up 10,934,154 of common stock as of 2017-03-27.

The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 10,934,154 representing a 46.7% stake in the company

For those not familiar with the company, Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.

A glance at Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s key stats reveals a current market capitalization of 375.12 Million based on 23.42 Million shares outstanding and a price at last close of $15.89 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-01-09, Baker picked up 32,051 at a purchase price of $17.76. This brings their total holding to 9,764,459 as of the date of the filing.

On the sell side, the most recent transaction saw Mackenzie unload 35,887 shares at a sale price of $18.67. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Esperion Therapeutics Inc. (NASDAQ:ESPR) is Attracting Smart Money

Mar 27, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Esperion Therapeutics Inc. (NASDAQ:ESPR) reported that Alta Partners Viii, L.p. has picked up 1,431,204 of common stock as of 2017-03-27.

The acquisition brings the aggregate amount owned by Alta Partners Viii, L.p. to a total of 1,431,204 representing a 6.3% stake in the company

For those not familiar with the company, Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

A glance at Esperion Therapeutics Inc. (NASDAQ:ESPR)’s key stats reveals a current market capitalization of 832.02 Million based on 22.56 Million shares outstanding and a price at last close of $38.27 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-21, Omenn picked up 1,000 at a purchase price of $42.46. This brings their total holding to 1,000 as of the date of the filing.

On the sell side, the most recent transaction saw Janney unload 700 shares at a sale price of $48.19. This brings their total holding to 1,359,967.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Esperion Therapeutics Inc. (NASDAQ:ESPR) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Celgene Switzerland Llc. Picked Juno Therapeutics Inc. (NASDAQ:JUNO) Shares

Celgene Switzerland Llc. Picked Juno Therapeutics Inc. (NASDAQ:JUNO) Shares

Mar 27, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Juno Therapeutics Inc. (NASDAQ:JUNO) reported that has picked up 10,350,833 of common stock as of 2017-03-27.

The acquisition brings the aggregate amount owned by Celgene Switzerland Llc. to a total of 10,350,833 representing a 9.7% stake in the company.

For those not familiar with the company, Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

A glance at Juno Therapeutics Inc. (NASDAQ:JUNO)’s key stats reveals a current market capitalization of 2.20 Billion based on 106.02 Million shares outstanding and a price at last close of $20.85 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-10, Evnin picked up 8,000 at a purchase price of $22.11. This brings their total holding to 56,990 as of the date of the filing.

On the sell side, the most recent transaction saw Azelby unload 12,921 shares at a sale price of $24.14. This brings their total holding to 35,719.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Juno Therapeutics Inc. (NASDAQ:JUNO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Guess Who Picked Up Mylan N.v. (NASDAQ:MYL) Shares

Guess Who Picked Up Mylan N.v. (NASDAQ:MYL) Shares

Mar 24, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mylan N.v. (NASDAQ:MYL), reported that Abbott Laboratories has picked up 25,750,000 of common stock as of 2017-03-24.

The acquisition brings the aggregate amount owned by Abbott Laboratories to a total of 25,750,000 representing a 4.81% stake in the company.

For those not familiar with the company, Mylan is a global healthcare company focused on making high quality medicines available to everyone who needs them. Its heritage of being a provider of generic pharmaceuticals goes back to its founding in West Virginia in 1961. Today, Mylan is passionate champions for better health around the world with a platform unmatched in the industry. They have one of the broadest and most diverse portfolios, with more than 7,500 marketed products that include prescription generic and brand-name medicines, and consumer healthcare products. Their healthcare services help patients to access products and adhere to medication regimens to help promote better health outcomes.

A glance at Mylan N.v. (NASDAQ:MYL)’s key stats reveals a current market capitalization of 22.33 Billion based on 535.50 Million shares outstanding and a price at last close of $41.60 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-06-03 Maroon picked up 1,670 at a purchase price of $44.95. This brings their total holding to 22,036 as of the date of the filing.

On the sell side, the most recent transaction saw Abbott unload 44,000,000 shares at a sale price of $41.60. This brings their total holding to 25,750,000.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Mylan N.v. (NASDAQ:MYL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more